Omicron COVID booster reduces hospitalization among those 65 and older, Israeli study shows – CTV

Jan. 9, 2023

JERUSALEM – The Omicron-adapted COVID-19 vaccine booster developed by Pfizer Inc and BioNTech SE sharply reduced hospitalizations among older patients, Israeli researchers said on Monday, in some of the first evidence of the jab’s real-world effectiveness.
The study by researchers from health-care provider Clalit, Ben-Gurion University of the Negev and Sapir College has not yet been peer reviewed.

It found an 81 per cent reduction in hospitalizations among people aged 65 and older who had received the booster against those who had previously received at least two COVID-19 vaccinations, but not the Omicron-adapted shot.

The study was carried out from the end of September until mid-December and looked at 622,701 people aged 65 and over who were eligible for the bivalent booster. Among them, 85,314, or 14 per cent, had received it.

Read more:

NationTalk Partners & Sponsors Learn More